Bio-Works Technologies AB (publ) (NGM:BIOWKS)
2.800
-0.050 (-1.75%)
At close: Feb 4, 2026
Bio-Works Technologies AB Revenue
Bio-Works Technologies AB had revenue of 16.64M SEK in the quarter ending September 30, 2025, with 69.64% growth. This brings the company's revenue in the last twelve months to 46.43M, up 22.56% year-over-year. In the year 2024, Bio-Works Technologies AB had annual revenue of 30.49M, down -30.55%.
Revenue (ttm)
46.43M
Revenue Growth
+22.56%
P/S Ratio
6.00
Revenue / Employee
1.60M
Employees
29
Market Cap
278.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 30.49M | -13.41M | -30.55% |
| Dec 31, 2023 | 43.90M | 2.58M | 6.23% |
| Dec 31, 2022 | 41.32M | -15.04M | -26.68% |
| Dec 31, 2021 | 56.36M | 49.13M | 679.08% |
| Dec 31, 2020 | 7.23M | 1.66M | 29.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 300.49M |
| Xbrane Biopharma AB | 259.70M |
| Intervacc AB | 21.09M |
| Elicera Therapeutics AB | 13.70M |
| Medivir AB | 3.88M |
| Xintela AB | 2.96M |
| Lipum AB | 398.00K |
| Mendus AB | -1.44M |